샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941472

오토인젝터(자동 주사기) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Autoinjectors Market Size, Share, & Trends Analysis By Product, By Indication, By End-use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 160 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

오토인젝터(자동 주사기) 시장 요약

세계의 오토인젝터 시장 규모는 2025년에 102억 달러로 추정되며, 2033년까지 284억 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 13.8%를 나타낼 것으로 예측됩니다. 자가주사기 시장은 당뇨병, 아나필락시스 등 만성질환 증가로 인해 사용하기 쉬운 약물 투여 시스템의 필요성이 대두되고 있는 것이 주요 촉진요인입니다.

자가투여의 장점에 대한 인식이 높아지고, 생물제제의 발전과 기술 혁신으로 인해 안전성과 사용 편의성이 향상되고 있습니다. 정부의 지원 정책, 의료비 지출 증가, 저침습적 장치에 대한 수요는 시장 성장을 더욱 촉진하고 있습니다.

오토인젝터는 효율적이고 진보된 약물전달 능력과 새로운 제제와의 호환성으로 인해 기존 장치보다 선호되고 있습니다. 주사바늘 공포증 및 불안감 감소, 주사바늘 찔림 사고 위험 감소, 투약 정확도 유지, 유효성 향상 등 다양한 이점이 있으며, 다양한 환자층에서 채택을 촉진하고 있습니다. 마찬가지로 집에서 투여할 수 있는 사용하기 쉬운 자동주사기의 가용성과 접근성이 향상되면서 그 채택이 더욱 확대되고 있습니다. 예를 들어 2024년 5월 미국 식품의약국(FDA)은 5세 이상의 루푸스 환아를 위한 벤리스타 자동주사기의 가정내 사용을 승인했습니다. 이번 승인은 치료의 접근성과 편의성을 향상시키고, 간병인이 의료기관 밖에서 약물을 투여할 수 있도록 하는 것을 목표로 하고 있습니다. 오토인젝터는 루푸스를 효과적으로 관리하기 위해 매우 중요한 치료 순응도를 높이기 위해 고안된 제품입니다.

또한 류마티스 관절염, 다발성 경화증, 아나필락시스 등의 질환은 잦은 주사가 필요하므로 사용의 용이성, 정확성, 환자 순응도 등의 장점으로 인해 오토인젝터가 선호되고 있습니다. 특히 면역학, 종양학 등 치료 영역에서 생물제제 및 바이오시밀러로의 전환이 수요를 더욱 촉진하고 있습니다. 바이오제약 기업은 환자 중심의 약물전달 기술에 적극적으로 투자하고 있으며, 오토인젝터가 보다 다양한 제형에 대응할 수 있도록 노력하고 있습니다. 또한 재택 치료 옵션의 확대와 자가 투여에 대한 선호도가 높아짐에 따라 이러한 장치의 채택을 더욱 촉진하여 의료시설의 부담을 줄이면서 환자의 치료 결과를 개선하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 오토인젝터 시장 변수, 동향, 범위

제4장 오토인젝터 시장 : 제품별 추정·동향 분석

제5장 오토인젝터 시장 : 적응증별 추정·동향 분석

제6장 오토인젝터 시장 : 최종 용도별 추정·동향 분석

제7장 오토인젝터 시장 : 지역별 추정·동향 분석

제8장 경쟁 구도

KSA

Autoinjectors Market Summary

The global autoinjectors market size was estimated at USD 10.2 billion in 2025 and is projected to reach USD 28.4 billion by 2033, growing at a CAGR of 13.8% from 2026 to 2033. The auto injectors market is driven by the increasing prevalence of chronic diseases such as diabetes and anaphylaxis, necessitating user-friendly medication delivery systems.

Rising awareness of self-administration benefits, advancements in biologics, and technological innovations enhance safety and ease of use. Supportive government policies, increased healthcare expenditure, and demand for minimally invasive devices further boost market growth.

Autoinjectors are preferred over conventional devices due to their efficient and enhanced drug delivery capabilities and compatibility with new formulations. They offer several benefits, including reduced needle phobia and anxiety, decreased risk of needle stick injuries, consistent dose accuracy, and improved efficacy, which drives their adoption in diverse patient pools. Similarly, the increasing availability and access to user friendly autoinjectors which can be administered at home is further increasing their adoption. For instance, in May 2024, the FDA approved the Benlysta autoinjector for at-home use in children aged 5 years and older with lupus. This approval aims to improve treatment accessibility and convenience, allowing caregivers to administer the medication outside of clinical settings. The autoinjector is designed to enhance patient adherence to therapy, which is crucial for managing lupus effectively.

Moreover, conditions such as rheumatoid arthritis, multiple sclerosis, and anaphylaxis require frequent injections, making auto-injectors a preferred option due to their ease of use, accuracy, and patient compliance benefits. The shift towards biologics and biosimilars, particularly in therapeutic areas such as immunology and oncology, is further fueling demand. Biopharmaceutical companies are actively investing in patient-centric drug delivery technologies, ensuring that auto-injectors are compatible with a broader range of formulations. In addition, the expansion of home-based treatment options and self-administration preferences has further strengthened the adoption of these devices, reducing the burden on healthcare facilities while improving patient outcomes.

Global Autoinjectors Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoinjectors market report on the basis of product, indication, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Disposable auto-injectors
  • Reusable auto-injectors
    • Prefilled
    • Empty
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Homecare Settings
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.1. Segment Definitions
    • 1.1.1. Product
    • 1.1.2. Indication
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecasts timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Indication outlook
    • 2.2.3. End Use outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Autoinjectors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of targeted therapies
      • 3.2.1.2. Increase in the incidence of anaphylactic shock
      • 3.2.1.3. Patients' preference to choose self-administration of injections
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Availability of its substitute products like general injections and oral tablets
  • 3.3. Auto-Injectors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Autoinjectors Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Autoinjectors Market: Product Movement Analysis
  • 4.3. AutoinjectorsMarket by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 4.5. Disposable Auto-Injectors
    • 4.5.1. Disposable Autoinjectors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reusable Auto-Injectors
    • 4.6.1. Reusable Autoinjectors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.6.1.1. Prefilled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.6.1.1.1. Prefilled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.6.1.2. Empty Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.6.1.2.1. Empty Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Autoinjectors Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Autoinjectors Market: Indication Movement Analysis
  • 5.3. AutoinjectorsMarket by Indication Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 5.5. Rheumatoid Arthritis
    • 5.5.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Multiple Sclerosis
    • 5.6.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Diabetes
    • 5.7.1. Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Anaphylaxis
    • 5.8.1. Anaphylaxis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Other Therapies
    • 5.9.1. Other Therapies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Autoinjectors Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Autoinjectors Market: End Use Movement Analysis
  • 6.3. Autoinjectors Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 6.5. Homecare Settings
    • 6.5.1. Homecare Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Hospitals & Clinics
    • 6.6.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Ambulatory Surgical Centers
    • 6.7.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Autoinjectors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Regional Autoinjectors Market movement analysis
  • 7.3. Autoinjectors Market: Regional Estimates & Trend Analysis by Product, Indication & End Use
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 7.5. North America
    • 7.5.1. North America Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. U.S.
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. U.S. Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Canada Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. Mexico Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Europe
    • 7.5.6. Europe Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. UK
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. UK Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Germany
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement scenario
      • 7.5.8.5. Germany Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. France
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement scenario
      • 7.5.9.5. France Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.10. Italy
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Competitive Scenario
      • 7.5.10.3. Regulatory Framework
      • 7.5.10.4. Reimbursement scenario
      • 7.5.10.5. Italy Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.11. Spain
      • 7.5.11.1. Key Country Dynamics
      • 7.5.11.2. Competitive Scenario
      • 7.5.11.3. Regulatory Framework
      • 7.5.11.4. Reimbursement scenario
      • 7.5.11.5. Spain Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.12. Denmark
      • 7.5.12.1. Key Country Dynamics
      • 7.5.12.2. Competitive Scenario
      • 7.5.12.3. Regulatory Framework
      • 7.5.12.4. Reimbursement scenario
      • 7.5.12.5. Denmark Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.13. Sweden
      • 7.5.13.1. Key Country Dynamics
      • 7.5.13.2. Competitive Scenario
      • 7.5.13.3. Regulatory Framework
      • 7.5.13.4. Reimbursement scenario
      • 7.5.13.5. Sweden Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.14. Norway
      • 7.5.14.1. Key Country Dynamics
      • 7.5.14.2. Competitive Scenario
      • 7.5.14.3. Regulatory Framework
      • 7.5.14.4. Reimbursement scenario
      • 7.5.14.5. Norway Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Japan Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. China Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. India Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement scenario
      • 7.6.5.5. South Korea Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement scenario
      • 7.6.6.5. Australia Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement scenario
      • 7.6.7.5. Thailand Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Brazil Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Argentina Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. South Africa Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. Saudi Arabia Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement scenario
      • 7.8.4.5. UAE Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement scenario
      • 7.8.5.5. Kuwait Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Share Analysis, 2025
  • 8.3. Key Company Profiles
    • 8.3.1. Eli Lilly
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. SHL Medical AG
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. AbbVie, Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Amgen
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Owen Mumford
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Ypsomed
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Teva Pharmaceutical
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Biogen Idec
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Mylan N.V.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Pfizer, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Sanofi
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Gerresheimer AG
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제